Breaking AI & Tech News Analyzed

Eli Lilly, the US pharmaceutical group behind the Mounjaro weight-loss drug, is seeking to resume its investments in the UK after pausing them last year. The company is in talks with UK ministers to regularly increase NHS drug prices and end a rebate scheme. Patrik Jonsson, president of Eli Lilly's international business, expressed optimism about reaching an agreement this summer.The talks will also explore 'innovative' pricing plans, such as linking payments for anti-obesity drugs to whether the treatment helps patients return to work. This comes as the US pharmaceutical industry increases pressure on the UK, with Keir Starmer agreeing to the first increase in NHS cost-effectiveness thresholds in 27 years. The threshold was raised from £20,000 to £30,000 a year for every year of life gained to £25,000 to £35,000.Eli Lilly was one of several pharmaceutical companies that ditched or paused almost £25bn in planned investments in the UK last year. The company paused its plans to invest in a laboratory site in central London. Jonsson stated that the resumption of Eli Lilly's investment would depend on the outcome of its talks with the government.He emphasized that prices for medicines in the UK had been 'far too low for far too long' and that the threshold couldn't remain static for another three decades. The UK agreed to pay 25% more for new medicines by 2035 as part of a US-UK drug pricing deal, which could eventually reach £9bn a year.Large pharmaceutical companies have protested about a 'rebate' scheme, under which they are required to pay back a chunk of revenue from sales of branded medicines. This scheme is expected to fall in 2026, although Jonsson believes payments 'should actually get down to zero' over time.

The UK is on the brink of a medicine shortage crisis, with experts warning that the country is just weeks away from feeling the effects of the ongoing conflict in Iran. The war has already disrupted the supply of essential raw materials, including oil, gas, crop fertiliser, and helium.The pharmaceutical industry, which relies heavily on imports, is particularly vulnerable to these disruptions. India, known as the 'pharmacy of the world', produces a significant proportion of generic drugs and active pharmaceutical ingredients (APIs) used globally. However, with the Strait of Hormuz largely closed due to the conflict, the transportation of these vital supplies is becoming increasingly difficult.Medicine prices are also expected to rise as a result of the conflict. The US-Israel war on Iran has doubled air freight costs, which could make some medicines loss-making to supply to the NHS. While suppliers have long-term pricing agreements with NHS hospitals, they have more flexibility to increase prices for drugs supplied to GP practices and pharmacies.The UK's reliance on imported medicines is significant, with about half of its medicines produced domestically, a third coming from India, and another chunk from the EU. During the Covid pandemic, paracetamol and other painkillers were in short supply in Britain and elsewhere, as drugmakers in India struggled to keep up with demand.Medical distributors typically stock six to eight weeks of supplies to avoid shortfalls, but if the conflict drags on, drug shortages could emerge in only a few weeks' time. Experts warn that the overall ripple effect on the industry is significant, with the patient ultimately picking up the tab, either directly or via public health systems like the NHS.

New York City's public hospital system has announced that it will not be renewing its contract with Palantir, a data analytics and AI firm, amid growing controversy over its government contracts in the UK. The decision comes as health officials in the UK express concerns over data privacy issues related to Palantir's £330m agreement with the National Health Service (NHS).The contract between NYC Health + Hospitals and Palantir, which focused on recovering money for insurance claims, was set to expire in October. According to documents shared with the Guardian, Palantir has paid nearly $4m to the hospital system since November 2023. The contract allowed Palantir to review patient health notes and help the hospital claim more money in public benefits through programs like Medicaid.Despite assurances from NYC Health + Hospitals that there was an 'absolute firewall' preventing Palantir from sharing information with US Immigration and Customs Enforcement (ICE), activists and data privacy experts have raised concerns over the potential risks of Palantir accessing de-identified patient data for purposes other than research.As New York City prepares to part ways with Palantir, the company is expanding its influence in the UK, despite backlash from activists and lawmakers. Palantir has contracts with the British government's Ministry of Defence and is seeking access to sensitive national financial regulation data through a contract with the Financial Conduct Authority.Medact, a health justice charity, has raised concerns that Palantir's software could enable 'data-driven state abuses of power', including US-style ICE raids. In response, Palantir has denied that its data could be used in this way, citing that it would be illegal and a breach of contract.The decision by NYC Health + Hospitals to drop Palantir has been hailed as a victory by activists, who are now calling on the NHS to follow suit and terminate its £330m contract with the company. The 'Purge Palantir' campaign, which involves nurses, pro-Palestinian activists, and social and climate justice groups, aims to stop Palantir from contracting with government agencies, universities, and corporations.

The UK government's recent announcement to make significant cuts to direct aid to Africa and the Middle East has been met with deep disappointment. This move is seen as a moral dereliction of duty, betraying the world's most marginalised, and a false economy that will bring greater instability to the world and make people less safe. The cut in aid to 0.3% of gross national income (GNI) from 2027 breaks Labour's 2024 manifesto pledge to restore development spending at the level of 0.7% of GNI “as soon as fiscal circumstances allow”. The UK is making the steepest proportion of aid cuts among G7 nations. As James Mattis, Donald Trump's defence secretary, once said: “If you don’t fund the state department fully, then I need to buy more ammunition ultimately.” This highlights the shortsightedness of cutting aid, which could lead to more conflict, famine, and persecution. The UK itself benefits materially from these investments. The recent inquiry by the all-party parliamentary group on global health and security on international health worker recruitment highlights the extent to which the NHS and wider economy rely on the skills, expertise, and partnerships rooted in the global south. The UK has saved £14bn in training costs through international recruitment and continues to depend on globally trained health professionals. Investment in global vaccination, disease surveillance, and research helps stop outbreaks before they spread internationally and place pressure on health systems. Preventing disease at source is one of the smartest investments we can make to protect patients in Britain. The situation in Somalia, on the edge of famine, underscores the importance of sustained investment in global development. Two consecutive failed rainy seasons have left 6.5 million people in crisis, more than double the number a year ago. The UK's humanitarian relief in Somalia is welcome, but the scrapping of nature funding and cuts to climate aid risk compromising its own strategy of preventing crisis before it takes hold.

A recent conversation with a guest at an academic function brought to light the public's desire for a simple, all-encompassing test for cancer. The guest, intrigued by the speaker's profession as an oncologist, inquired about the existence of an 'everything' test for cancer. The speaker's response was clear: no such test exists.The quest for early cancer detection is a significant goal in cancer medicine, with the aim of identifying the disease before it metastasizes and ensuring a cure. One company, Grail, launched a blood test called Galleri, which claims to detect a 'signal' shared by more than 50 types of cancer. This signal is identified through circulating DNA, minute fragments of cancer DNA present in the bloodstream.The Galleri test was marketed as a screening tool, with results indicating either a cancer signal detected or no cancer signal detected. However, the test failed to meet its primary endpoint in a large-scale trial conducted with the NHS, which aimed to determine if the test could reduce late-stage cancer diagnoses. Despite the company's claims of 'strong' results, the trial did not demonstrate a significant reduction in late-stage cancer diagnoses.The failure of the Galleri test highlights a crucial distinction between detecting more cancers and saving lives. Detecting cancer at an early stage does not necessarily translate to less invasive treatments or prolonged survival. Moreover, some cancers detected through screening may never have posed a lethal threat, leading to unnecessary interventions.For now, there is no blood test or total body scan that saves lives. Instead, the focus should be on modifying cancer risk factors, such as reducing processed foods, curbing alcohol consumption, quitting smoking, and engaging in regular exercise. These evidence-based approaches may not be as flashy as a single 'everything' test, but they have a proven impact on public health.

UK MPs have called on the government to halt a contract with Palantir, a US-based spy-tech company, after it was revealed that the firm will gain access to a vast trove of highly sensitive UK financial regulation data. The Financial Conduct Authority (FCA), the watchdog overseeing thousands of financial bodies, has hired Palantir to apply its AI systems to two years' worth of internal intelligence data to help tackle financial crime. However, the Liberal Democrats and Green party have raised concerns over Palantir's ties to Donald Trump and the potential risks to national and economic security. The Liberal Democrats have called for a government investigation into the contract, citing concerns that it could be "a huge error of judgment". Palantir, founded by Peter Thiel, a billionaire supporter of Trump, has built up over £500m in contracts in the UK, including with the NHS, police, and Ministry of Defence. The company supports the US and Israeli militaries and the ICE immigration crackdown. Insiders at the FCA have questioned whether there are sufficient safeguards in place to prevent the data from being exploited. There are concerns about the potential for data about sensitive FCA investigations into high-profile figures to be accessed during Palantir's work. The FCA has insisted that Palantir will be a "data processor", not a "data controller", meaning it can only act on instruction from the regulator. The FCA will retain exclusive control over the encryption keys for the most sensitive files, and the data will be hosted and stored solely in the UK. Despite these assurances, MPs have expressed concerns over the risks associated with the contract. Daisy Cooper, the Liberal Democrats' Treasury spokesperson, called for an investigation into the FCA's Palantir contract, citing concerns over Palantir's ties to Trump. The Green party MP Siân Berry has called for the government to "step in immediately and protect our national and economic security by blocking this contract award". Palantir has denied claims that it may "use customer data for our own purposes", stating that this is "something that we have no business interest in, and that we are legally and contractually prevented from doing".

Scotland has taken a significant step in the early detection and treatment of spinal muscular atrophy (SMA), a rare genetic condition that causes progressive muscle wastage, by becoming the first part of the UK to screen newborn babies for the condition.The screening, which is part of the existing heel prick test offered to all parents in Scotland about four days after birth, is funded by the Scottish government and pharmaceutical company Novartis. The goal is to assess how well screening can detect SMA earlier, allowing babies to receive treatment as soon as possible.SMA affects an estimated 1 in 14,000 births worldwide and impacts movement, breathing, and swallowing. Without treatment, it can limit life expectancy to two years. The condition was brought to wider attention after former Little Mix singer Jesy Nelson revealed in January that her twin daughters had been diagnosed with SMA.Campaigners, who have long advocated for newborn testing, hope the Scottish pilot will result in approval for the heel prick test across the UK. Giles Lomax, chief executive of SMA UK, said the screening pilot in Scotland would be “a huge impetus for other parts of the UK to speed up their own testing plans”. He hopes the Scotland trial will provide data that would convince the UK National Screening Committee to approve UK-wide testing.There is no cure for SMA, but there are now three NHS-funded drug treatments available. Lomax emphasized that with these treatments and newborn screening, “the future for anyone diagnosed with SMA is very different compared to their peers who were diagnosed symptomatically. It basically gives children the life they deserve.”

Palantir, a leading AI and data analytics company, has secured a major contract with the UK's Financial Conduct Authority (FCA) to leverage its AI technology for detecting financial wrongdoing. This deal marks a significant expansion of Palantir's presence in the UK, where it has already embedded its technology in the NHS, police, and military. The contract, valued at over £500m, enables Palantir to access terabytes of data gathered by the FCA, providing it with an unparalleled view of the inner workings of British authorities and the City of London, a global financial hub. Campaign groups have expressed concerns over Palantir's work with public authorities, citing its previous involvement with controversial entities such as the US Department of Homeland Security and the Israel Defense Forces. However, the company continues to secure lucrative contracts in the UK. The FCA aims to utilize Palantir's AI technology to better detect signs of wrongdoing, such as money laundering and fraud, which account for approximately 40% of all crimes in the UK. The regulator's workplan for 2025-26 includes expanding the use of data and intelligence to identify and act on high-risk firms and individuals. However, experts warn that the use of AI in detecting financial wrongdoing may lead to new challenges, such as criminals adapting to evade detection by using techniques like invisible 'white text' in documents to instruct AI systems to ignore incriminating information. Prof Michael Levi, an expert in money laundering at Cardiff University, notes that while there are concerns about data privacy, the use of AI technology can also help target corporate holdings and shell companies used for illicit activities.

The recent meningitis outbreak in Kent has tragically claimed the lives of two young people, with 18 confirmed cases and 11 others being investigated. The outbreak, which has affected four schools and two universities in the Canterbury area, has disrupted thousands of lives and understandably instilled fear among many.The public health response, including contact-tracing, treatment with preventive antibiotics, and localized vaccinations, appears to have been effective in limiting the spread of the disease. The NHS has administered about 2,500 vaccines and issued almost 10,000 precautionary doses of antibiotics.The meningitis B (MenB) strain of bacteria behind this outbreak has caused septicaemia and infection of the membranes surrounding the brain and spinal cord. Despite scientists not fully understanding what causes meningococcal bacteria to become invasive, the public health system has been able to manage the situation.The incident serves as a reminder of the importance of maintaining effective public health systems and the need for evidence-driven decision-making in responding to outbreaks. The UK's success in tackling infectious diseases, including a dramatic reduction in meningococcal disease deaths, is a testament to the effectiveness of prevention, vaccination, and improved treatment.As the risk of future pandemics remains, it is crucial that politicians and the public are reminded of the vital role of public health systems in preventing and managing outbreaks. The abolition of NHS England and its impact on the existing structure overseeing infection prevention and control will require careful consideration.